Skip to content
AnalystLens

Amrize 8-K Report, Financial Results (Aug 6, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed August 6, 2025
Period End
August 6, 2025
Security
AMRZ
In the record · 2025–202610-K110-Q58-K20

AMRZ filed 1 annual reports (10-K), 5 quarterly reports (10-Q) and 20 current reports (8-K) between 2025 and 2026.

  1. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Amrize Ltd (NYSE/SIX: AMRZ), the North American building materials company spun off from Holcim, reported second quarter 2025 results on August 6, 2025, its first quarterly report as a standalone public company following its June 23, 2025 listing.

Revenue was essentially flat at $3,220 milliona (down 0.7% year over year), while net income fell 9.5% to $428 million and diluted EPS declined to $0.78 from $0.86. Adjusted EBITDA decreased 5.6% to $947 million, with adjusted EBITDA margin contracting 150 basis points to 29.4%. Management attributed the softness to inclement weather, higher interest rates weighing on residential and commercial new construction, and $42 million of standalone corporate costs that were not present in the prior-year carve-out figures.

Excluding those costs, the company says margins were stable at 30.7%. The quarter's strategic and balance sheet developments were more notable. Amrize launched its ASPIRE cost program, targeting more than $250 millionb in cumulative synergies through 2028 and over 50 basis points of annual margin improvement, with incremental savings beginning in the second half of 2025 and a full run rate in 2026.

The company also established its standalone capital structure, raising $5.3 billionc of senior notes and drawing $930 million under a $2 billion commercial paper program. Gross debt stood at $6.2 billion and net debt at $5.6 billion, a net leverage ratio of 1.8x, with a target below 1.5x by year-end 2025. Credit ratings are BBB+ (S&P) and Baa1 (Moody's), both stable.

Full-year 2025 guidance calls for revenue of $11.4 to $11.8 billiond and adjusted EBITDA of $2.9 to $3.1 billion. For investors, the key takeaways are a resilient top line and margin profile in a soft volume environment, a meaningful cost-reduction program, and a materially re-levered balance sheet that now carries investment-grade ratings. The main watch items are the continued drag from standalone corporate costs, weak residential and commercial volumes (cement volumes down 6.3%, aggregates down 2.9%), and whether the ASPIRE savings and pricing discipline can offset them as the company executes its growth capital program.

02—Key points

Key Highlights

  1. Q2 2025 revenue of $3,220M was roughly flat (-0.7% YoY), with Building Materials at $2,250M (-1.1%) and Building Envelope at $970M (+0.1%, helped by the Ox Engineered Products acquisition).
  2. Net income declined 9.5% to $428M and diluted EPS fell to $0.78 from $0.86; H1 2025 net income was $341M, down 20.5%.
  3. Adjusted EBITDA fell 5.6% to $947M and margin compressed 150 bps to 29.4%, including $42M of standalone corporate costs; excluding these costs, margin was 30.7%.
  4. ASPIRE cost program targets $250M+ in synergies through 2028 and 50+ bps of annual margin improvement, with full run-rate savings expected from 2026.
  5. Balance sheet established post-spin: $5.3B senior notes issued, $930M commercial paper drawn, gross debt of $6.2B, net leverage of 1.8x, targeted below 1.5x by year-end 2025; ratings BBB+/Baa1 stable.
  6. FY2025 guidance: revenue of $11.4B-$11.8B, adjusted EBITDA of $2.9B-$3.1B, capex of about $700M, D&A of about $850M, and a 22%-24% effective tax rate.
  7. Growth investments include the Langley Concrete acquisition in British Columbia, a new Oklahoma aggregates quarry (~200M tons of reserves), 660K tons of cement capacity at Ste. Genevieve in Q4 2025, and a Malarkey shingle plant in Indiana due in H2 2026.

03—Questions

Frequently Asked Questions

  1. Why did adjusted EBITDA decline in the second quarter despite relatively stable revenue?

    Adjusted EBITDA fell 5.6% to $947M, mainly because of $42M in standalone corporate costs that were not included in the 2024 carve-out results. Weather, softer volumes (cement down 6.3%, aggregates down 2.9%) and higher interest rates also weighed on demand, though pricing was up (cement +0.5%, aggregates +6.7%) and partially offset the volume decline. Management says margins were stable excluding the standalone costs.

  2. How much debt does Amrize carry and how levered is it?

    As of June 30, 2025, gross debt was $6.2B, consisting of $931M in short-term borrowings and $5.26B in long-term debt, against $601M of cash, for net debt of $5.6B. The net leverage ratio is 1.8x trailing adjusted EBITDA, and management targets below 1.5x by year-end 2025.

  3. What is the ASPIRE program and when will it affect results?

    ASPIRE is a cost and synergy initiative targeting more than $250M in cumulative savings from 2025 through 2028 and over 50 bps of annual margin improvement. It spans raw material sourcing, services and procurement, logistics, and equipment. Incremental savings are expected to begin in H2 2025, with the full annual run rate starting in 2026.

  4. Is the company's full-year 2025 outlook intact?

    The company issued FY2025 targets of $11.4B-$11.8B in revenue and $2.9B-$3.1B in adjusted EBITDA, with a year-end net leverage ratio below 1.5x. The filing does not state whether these targets were revised from prior expectations, since Amrize had no prior public guidance as a standalone company.

04—Continue

← View all 8-K filings